+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 55Years
All Genders
Healthy Volunteers
ID07879170

Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Pharmacokinetics of Single and Multiple Ascending Doses of EPX-100 in Healthy Adults

Led by Epygenix · Updated on 2026-10-16

88

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, and pharmacokinetics of EPX-100 in healthy adult participants through a two-part study. Part 1 focuses on single ascending doses SAD of EPX-100, while Part 2 investigates multiple ascending doses MAD, including assessment of cardiac effects in each group. This randomized, double-blind, placebo-controlled study also includes a positive control to compare effects. Participants in Part 1 receive sequential single ascending doses of EPX-100 or matching placebo. In Part 2, participants receive EPX-100 twice daily for 13 days and a morning dose on Day 14, with placebo controls including moxifloxacin or its matching placebo in a crossover design. The study evaluates EPX-100s pharmacokinetics and safety during both single and multiple dose phases. During the trial, participants undergo various assessments including monitoring for treatment-emergent adverse events, pharmacokinetic sampling of plasma and urine, and electrocardiogram ECG evaluations to check cardiac intervals. The study tracks safety and tolerability up to Day 18 for Part 1 and Day 31 for Part 2. The total participation period varies depending on the study part and dosing schedule, with careful monitoring throughout.

CONDITIONS

Brief Title

A Single and Multiple Ascending Dose Study of EPX-100 in Healthy Adult Participants

Research Team

C

Clinical Trials Administrator

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here